Commercial Credit Report for Oxurion NV

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for Oxurion NV is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	Oxurion NV
Gaston Geenslaan 1
Phone: +32 16751310p:+32 16751310	LEUVEN (LOUVAIN), 3001 Belgium	Ticker: OXUROXUR

Business Summary

Oxurion NV, formerly known as ThromboGenics NV, is a Belgium-based biopharmaceutical company, which focuses on the development and commercialization of ophthalmic medicines. Its lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. Oxurion partners with Alcon (Novartis) for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns, which was launched in the United Kingdom and Germany. In addition, it also explores anti-PIGF (Placental Growth Factor), also referred to as TB-403, for the treatment of ophthalmic and oncology indications. The Company is active domestically, as well as operates through offices located in the United States and Ireland.

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
Yes	Yes	-	Yes	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
12/31/2023	12/31/2023	Yes	-	-	-	-

Industries

SIC Code	Description
8049	Offices and clinics of health practitioners, not elsewhere classified
8731	Commercial physical and biological research
2834	Pharmaceutical preparations

Officers and Directors

Title	Name	Title Date	Start Date
Chief Executive Officer, Chief Financial Officer, Director	PascalGhoson	12/29/2023	12/29/2023
Chief Legal Officer and Compliance Officer, Member of the Executive Committee	KathleenPaisley	1/1/2021	1/1/2020
Chief Business Officer, Company Secretary, Member of the Executive Committee	MichaelDillen	1/1/2021	3/1/2020
6 additional Officers and Directors records available in full report.

Business Names

Business Name
0G99
Oncurious NV
OXUR
4 additional Business Names available in full report.

General Information

Number of Employees:	20	(As of 12/31/2023)
Outstanding Shares:	9,014,821,287	(As of 3/27/2024)
Stock Exchange:	EBR
Fax Number:	+32 16751311

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN